Voice of Regenerative Medicine : Nobel Assembly Got Sued for Awarding ISSCR Stem Cell Con Man

Wednesday, April 10, 2013

Nobel Assembly Got Sued for Awarding ISSCR Stem Cell Con Man

We’d like to carry the story on Voice of Regenerative Medicine about FIRST LAW SUIT FILED AGAINST NOBEL PRIZE ORGANIZATION CITING DEFAMATION AND UNFAIR COMPETITION PRACTICES. Yamanaka of International Society for Stem Cell Research (ISSCR) put 4 oncogenes into the skin cells of lab rats, then claimed that he had made the safe adult cell alternate of pluripotent human embryonic stem cells (hESCs) by calling it as the induced pluriptoent stem cells (iPS cells) without any scientific evidence for the long-term stable self-renewal of stem cells by the definition of stem cells. The iPS cell of Yamanaka is more accurately known as the induced pluripotent somatic cell or the artificially reprogrammed adult cell. Although scientific term is mandated to be as accurate as possible, Yamanaka’s iPS cell term could not be any more confusing and far away from the truth. Anyone (not short of list) who had done what Yamanaka did before all had the scientific integrity to call what they had done as cancer studies. The only difference is what Yamanaka did was published in the prestigious top scientific Journal “Cell” (How?) that had been quickly endorsed and followed by a group of prestigious scientists of ISSCR that include the “father of stem cell” Jamie Thomson and Rudy Jaenisch and George Daley of Harvard, and had a committee of big names to campaign for Nobel prize for him with sugar-coated hidden political interest or agenda. The iPS abnormal cell of Yamanaka of ISSCR is a serious stem cell scam or fraud committed by someone who has no scientific integrity, misleading the stem cell community and general public to waste the public and taxpayers’ money enormously. The iPS abnormal cells of Yamanaka of ISSCR have created unfair competition practices for normal stem cell research and have stalled human embryonic stem cell research. Please see our blogs about it, such as “CIRM Embezzle State Fund and Resources to Waste on Induced Adult Stem Cell Scam (CIRM iPS Cell Initiative) Against Prop 71 – ISSCR Stem Cell Conman’s Thick Skin”, “CIRM’s iPS Cell Initiative — The Cloning Saga of ISSCR”, “Human Embryonic Stem Cells: The Most Positive Stem Cells — The Positivity CIRM Not Get”, “Frenzy over Reprogramming — Nobel Prize Condescended to Cooked Stem Cell Fraud”, “CIRM Lucrative RFAs Make Prop71 Stem Cell Research Impossible to Get Lawful Public Funds whereas Give Unlawful Frauds the Green Light”, “iPS Cells or Man-Made Junk”.

Quote from James Watson: “You could sequence 150,000 people with cancer and it’s not going to cure anyone ---”, “most of the experiments we do are irrelevant (to find a cure) ---”.

MEBO International: We wanted to reach out about the newest developments in Chinese researcher Rongxiang Xu's lawsuit against the Nobel Assembly as well as recent statements by James Watson regarding the ineffectiveness of genetic sequencing. Please take a look to see if this is would interest your readers, as both have relevance for the future of regenerative medicine

Human’s Innate Regenerative Ability

After Nobel’s assertion that his lawsuit is frivolous, Xu is seeking clarification on misstatements made in awarding the 2012 Nobel Prize. The suit was filed against the Nobel Assembly to clarify essential scientific details that Dr. Xu believed were misstated in their October 2012 Nobel prize announcement. Errors made in the statements not only discredit Dr. Xu's science (which has illustrated innate regenerative potential), but also involve the health and safety of people worldwide.

Xu is urging the Assembly to distinguish whether or not the human regenerative potential is innate or must be artificially created.

Background

Rongxiang Xu’s work in applied regenerative restoration science has implications in many medical fields, including helping severe burn victims and potentially assisting in the fight against cancer. With James Watson’s recent comments regarding the ineffectiveness of genetic sequencing, the growing need for stem cell research and regenerative medicine has made this topic even more relevant.

For more background on James Watson’s statements and Dr. Xu’s lawsuit:

UT San Diego - “Watson dings genetics, Irish, fellow Nobelist”: http://bit.ly/Yr5WCB

The Scientist - “Snubbed for a Nobel”: http://bit.ly/X96rjG

Sacramento Bee - “Nobel Assembly Attempts to Downplay Lawsuit with Dr. Rongxiang Xu”: http://bit.ly/10eNuw7

You can also learn more at the MEBO International Website or visit the MEBO International Facebook Page.

No comments:

Post a Comment

Public Interest

The successful derivation of human embryonic stem cell (human ES cell) lines from the in vitro fertilization (IVF) leftover embryos is considered as one of the major breakthroughs of the life sciences. The pluripotent human ES cells, derived from the inner cell mass (ICM) or epiblast of human blastocyst or human embryos, have both the unconstrained capacity for long-term stable undifferentiated growth in culture and the intrinsic potential for differentiation into all somatic cell types in the human body, holding tremendous potential for human tissue and function restoration. Therefore, human ES cells have been regarded as an ideal source to provide an unlimited supply of large-scale well-characterized human specialized cell types for cell-based therapies to resolve some worldwide major health problems, such as neurodegenerative diseases, paralysis, diabetes, and heart diseases. A small portion of the millions of excess embryos currently stored in the IVF clinics worldwide, which are otherwise destined for destruction, could potentially be an unlimited source to deliver in the future a whole range of therapeutic treatments for tissue and function restoration in patients with life-threatening diseases and injuries. However, human ES cell research has generated intense public interest as well as controversy due to concerns of products of human ES cell cultures that can only be obtained by the use, involving their destruction, of human embryos. The recent years’ court battles on Federal funding for human ES cell research in the United State (US) as well as the patentability of US and international patents directed to human ES cell technologies have also highlighted the decade long ethical, moral, social, and legal controversy surrounding the public interest of human ES cells involving destruction, commercial or industrial uses of human embryos. As neurodegenerative and heart diseases incur exorbitant costs on the healthcare system worldwide, there is a strong focus on providing newer and more efficient solutions for these therapeutic needs. Millions of people are pinning their hopes on human ES cell research. California voters have passed Proposition 71 to designate $3B public fund to support pluripotent human ES cell research and therapy development for the benefit of public health. In spite of ethical debates surrounding the ownership and funding issues of human ES cells, in the case of many incurable or hitherto untreatable life-threatening or devastating diseases, supporting human ES cell research is crucial to driving the advance of medicine to provide optimal regeneration and reconstruction treatment options to improve the function, wellness, and overall quality of life. To answer the intense public interest surrounding human ES cell research and enormous public healthcare benefits thereof, Voice of Regenerative Medicine provides a ground of public debate or voice or blog for the controversies surrounding public interest of human ES cells centering on scientific, economic, ethical, moral, social, financial conflict of interest, and legal issues, to increase public awareness and understanding of the scientific advancement of human ES cell research, and of the importance, urgency, and tangible benefits of human ES cell-based regenerative medicine to improving the function, wellness, and overall quality of life for patients suffering from incurable or hitherto untreatable life-threatening or devastating diseases; to increase public support for human ES cell research; to improve policy making and funding situation for human ES cell research, and to identify and disclose publicly those scientific, economic, ethical, moral, social, financial conflict of interest, and legal issues that have impeded the progress of human ES cell research and stem cell therapy development, introduction of medical innovations and new business opportunities based on human ES cell research, and bringing new therapeutics into the market.

Disclaimer:

This “Voice of Regenerative Medicine” blog is to provide a public voice and an open forum to human embryonic stem cell research and regenerative medicine start-up. All content provided on this blog is for informational purposes only. This blog makes no representations as to accuracy, completeness, correctness, reliability, suitability, or validity of any information on this site or found by following any link on this site, and will not be liable for any errors or omissions or availability in this information, or any losses, injuries, or damages arising from the display or use of this information. The inclusion of any content, images, documents, files, and links on the blog does not necessarily imply a recommendation or endorse the views expressed within them. The content of any postings or comments on the blog do not necessary reflect or do not necessary represent the positions, strategies, views, or opinions of the owners, authors, bloggers, or San Diego Regenerative Medicine Institute or any organizations or any companies or any director, officer, or employee thereof. This blog is not associated with, affiliated with, a partner with, belonging to, or acting upon any organizations or individuals. The blog’s content is not generated to make money or paid for blogging content. It is natural for the content on the blog to be controversial or contentious. The content on the blog is the opinion only, not intended to malign any religion, ethnic group, club, organization, company, or individual, or anyone or anything. The owners, bloggers, San Diego Regenerative Medicine Institute, any individuals, any organizations, and any companies are not responsible, nor will be held liable, for the content or comments or the display or use of any information on the blog. Our intention is to do no harm, to not injure others, defame, or libel. All information is provided on an as-is basis. These terms and conditions are subject to change at anytime and without notice.